Related references
Note: Only part of the references are listed.LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial
B. Zambrowicz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Examining the Effects of Hyperglycemia on Pancreatic Endocrine Function in Humans: Evidence for in Vivo Glucotoxicity
Thomas P. J. Solomon et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Dale S. Edgerton et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Insulin resistance, endocrine function and adipokines in type 2 diabetes patients at different glycaemic levels:: potential impact for glucotoxicity in vivo
S. Lindmark et al.
CLINICAL ENDOCRINOLOGY (2006)
Dose-response effect of elevated plasma free fatty acid on insulin signaling
R Belfort et al.
DIABETES (2005)
Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients
AY Mayorov et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2005)
Microvascular complications of diabetes
ZH He et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2004)
Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog
SM Gustavson et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients:: Is cellular insulin resistance caused by glucotoxicity in vivo?
J Burén et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals
M Matsuda et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)